Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5266693
Max Phase: Preclinical
Molecular Formula: C17H17Cl2N7O
Molecular Weight: 406.28
Associated Items:
ID: ALA5266693
Max Phase: Preclinical
Molecular Formula: C17H17Cl2N7O
Molecular Weight: 406.28
Associated Items:
Canonical SMILES: Cc1nnc2ccc(N3CCN(C(=O)Nc4ccc(Cl)c(Cl)c4)CC3)nn12
Standard InChI: InChI=1S/C17H17Cl2N7O/c1-11-21-22-15-4-5-16(23-26(11)15)24-6-8-25(9-7-24)17(27)20-12-2-3-13(18)14(19)10-12/h2-5,10H,6-9H2,1H3,(H,20,27)
Standard InChI Key: SDFBKYGPBZEQMU-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 406.28 | Molecular Weight (Monoisotopic): 405.0872 | AlogP: 3.09 | #Rotatable Bonds: 2 |
Polar Surface Area: 78.66 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 13.12 | CX Basic pKa: 2.09 | CX LogP: 2.71 | CX LogD: 2.71 |
Aromatic Rings: 3 | Heavy Atoms: 27 | QED Weighted: 0.71 | Np Likeness Score: -2.89 |
1. Oboh E, Teixeira JE, Schubert TJ, Maribona AS, Denman BN, Patel R, Huston CD, Meyers MJ.. (2023) Structure-Activity relationships of replacements for the triazolopyridazine of Anti-Cryptosporidium lead SLU-2633., 86 [PMID:37148788] [10.1016/j.bmc.2023.117295] |
Source(1):